The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old

Chest

Volumn 127, Issue 2, 2005, Pages 509-514

  Straub, Daniel A ^a   Minocchieri, Stefan ^a   Moeller, Alexander ^a   Hamacher, Jürg ^b   Wildhaber, Johannes H ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Airway resistance; Asthma; Bronchodilator responsiveness; Inflammation; Lung function test; Montelukast; Nitric oxide; Preschool children

Indexed keywords

MONTELUKAST; NITRIC OXIDE;

AIRWAY RESISTANCE; ALLERGIC ASTHMA; ALLERGY TEST; ARTICLE; BRONCHODILATATION; DISEASE PREDISPOSITION; DRUG EFFECT; EXPIRATORY FLOW RATE; FAMILY HISTORY; FEMALE; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME; WHEEZING;

EID: 13644254648     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.2.509     Document Type: Article

References (38)

1. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev (database online). Issue 2, 2000
2. Roorda RJ, Mezei G, Bisgaard H, et al. Response of preschool children with asthma symptoms to fluticasone propionate. J Allergy Clin Immunol 2001; 108:540-546
3. Volovitz B, Bentur L, Finkelstein Y, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol 1998; 102:605-609
4. Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life: the Group Health Medical Associates. N Engl J Med 1995; 332:133-138
5. Martinez FD. Present and future treatment of asthma in infants and young children. J Allergy Clin Immunol 1999; 104:169-174
6. Kharitonov SA, Yates D, Springall DR, et al. Exhaled nitric oxide is increased in asthma. Chest 1995; 107:156S-157S
7. Byrnes CA, Dinarevic S, Shinebourne EA, et al. Exhaled nitric oxide measurements in normal and asthmatic children. Pediatr Pulmonol 1997; 24:312-318
8. Wildhaber JH, Hall GL, Stick SM. Measurements of exhaled nitric oxide with the single-breath technique and positive expiratory pressure in infants. Am J Respir Crit Care Med 1999; 159:74-78
9. Baraldi E, Dario C, Ongaro R, et al. Exhaled nitric oxide concentrations during treatment of wheezing exacerbation in infants and young children. Am J Respir Crit Care Med 1999; 159:1284-1288
10. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999; 160:1227-1231
11. Wildhaber JH, Moeller A, Hall GH, et al. Levels of exhaled nitric oxide in recurrently wheezy infants are decreased following inhaled steroid therapy. Schweiz Med Wochenschr 2000; 130:529-534
12. Kanengiser S, Dozor AJ. Forced expiratory maneuvers in children aged 3 to 5 years. Pediatr Pulmonol 1994; 18:144-149
13. Phagoo SB, Wilson NM, Silverman M. Evaluation of a new interrupter device for measuring bronchial responsiveness and the response to bronchodilator in 3 year old children. Eur Respir J 1996; 9:1374-1380
14. Beydon N, Amsallem F, Bellet M, et al. Pre/postbronchodilator interrupter resistance values in healthy young children. Am J Respir Crit Care Med 2002; 165:1388-1394
15. Salmon B, Wilson NM, Silverman M. How much aerosol reaches the lungs of wheezy infants and toddlers? Arch Dis Child 1990; 65:401-403
16. Hay DW, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995; 16:304-309
17. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001; 56:7-11
18. Narayanan S, Edelman JM, Berger ML, et al. Asthma control and patient satisfaction among early pediatric users of montelukast. J Asthma 2002; 39:757-765
19. Klug B, Nielsen KG, Bisgaard H. Observer variability of lung function measurements in 2-6-yr-old children. Eur Respir J 2000; 16:472-475
20. Recommendations for standardized procedures for the online and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. Am J Respir Crit Care Med 1999; 160:2104-2117
21. Global Initiative for Asthma. GINA guidelines: global strategy for asthma management and prevention revised (2002). Bethesda, MD: National Institutes of Health, 2002; publication No. 02-3659
22. Berkman N, Avital A, Bardach E, et al. The effect of montelukast on bronchial provocation tests and exhaled nitric oxide levels in asthmatic patients. Isr Med Assoc J 2003; 5:778-781
23. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133:424-428
24. Minoguchi K, Kohno Y, Minoguchi H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002; 121:732-738
25. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58:211-216
26. Bratton DL, Lanz MJ, Miyazawa N, et al. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 1999; 28:402-407
27. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol 2002; 109:257-263
28. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:E48
29. Lim S, Jatakanon A, John M, et al. Effect of inhaled budesonide on lung function and airway inflammation: assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 1999; 159:22-30
30. Berlyne GS, Parameswaran K, Kamada D, et al. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. J Allergy Clin Immunol 2000; 106:638-644
31. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996; 153:454-457
32. Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol 2003; 111:256-262
33. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-418
34. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial: Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487-495
35. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350:1599-1600
36. Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55:S28-S31
37. Mastalerz L, Nizankowska E, Sanak M, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002; 32:949-955
38. Whelan GJ, Blake K, Kissoon N, et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444)C polymorphism. Pediatr Pulmonol 2003; 36:413-420